VKA in RHD patients with MHV: our current status
Vitamin K Antagonist in Rheumatic heart disease patients with mechanical heart valves: Our Current Status
Study Type
OBSERVATIONAL
Enrollment
165
Time in therapeutic range (TTR) for warfarin.
TTR status will be calculated using the most recent INR value and patient records to determine whether INR is within the target therapeutic range (2.0-3.5) at the time of data collection.
Time frame: Baseline
2. Correlation Between TTR and Patient-Specific Factors
Assesses the relationship between INR control and factors such as age, comorbidities, adherence, vitamin K intake, and medication use based on data collected at the single study visit.
Time frame: Baseline
1. Number of Participants With Reported Bleeding Events (Major or Minor)
Presence or absence of self-reported or documented major/minor bleeding events prior to or at the time of data collection.
Time frame: Baseline
Number of Participants With Thromboembolic Events
History of stroke, valve thrombosis, or systemic embolism collected from medical records or patient report during the study visit.
Time frame: Baseline
Rate of Patient Adherence to Warfarin Therapy
Adherence assessed via patient self-report and/or pill count at the single study visit.
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.